Frontiers in Immunology (May 2022)
One Shoot, Two Birds: Alleviating Inflammation Caused by Ischemia/Reperfusion Injury to Reduce the Recurrence of Hepatocellular Carcinoma
- Hao Chen,
- Hao Chen,
- Hao Chen,
- Di Lu,
- Di Lu,
- Di Lu,
- Xinyu Yang,
- Xinyu Yang,
- Xinyu Yang,
- Zhihang Hu,
- Zhihang Hu,
- Zhihang Hu,
- Chiyu He,
- Chiyu He,
- Chiyu He,
- Chiyu He,
- Huigang Li,
- Huigang Li,
- Huigang Li,
- Zuyuan Lin,
- Zuyuan Lin,
- Zuyuan Lin,
- Modan Yang,
- Modan Yang,
- Modan Yang,
- Xiao Xu,
- Xiao Xu,
- Xiao Xu,
- Xiao Xu
Affiliations
- Hao Chen
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Hao Chen
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Hao Chen
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Di Lu
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Di Lu
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Di Lu
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Xinyu Yang
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Xinyu Yang
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Xinyu Yang
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Zhihang Hu
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Zhihang Hu
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Zhihang Hu
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Chiyu He
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Chiyu He
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Chiyu He
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Chiyu He
- Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China
- Huigang Li
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Huigang Li
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Huigang Li
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Zuyuan Lin
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Zuyuan Lin
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Zuyuan Lin
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Modan Yang
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Modan Yang
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Modan Yang
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Xiao Xu
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Xiao Xu
- National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- Xiao Xu
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China
- Xiao Xu
- Westlake Laboratory of Life Sciences and Biomedicine, Westlake University, Hangzhou, China
- DOI
- https://doi.org/10.3389/fimmu.2022.879552
- Journal volume & issue
-
Vol. 13
Abstract
Inflammation is crucial to tumorigenesis and the development of metastasis. Hepatic ischemia/reperfusion injury (IRI) is an unresolved problem in liver resection and transplantation which often establishes and remodels the inflammatory microenvironment in liver. More and more experimental and clinical evidence unmasks the role of hepatic IRI and associated inflammation in promoting the recurrence of hepatocellular carcinoma (HCC). Meanwhile, approaches aimed at alleviating hepatic IRI, such as machine perfusion, regulating the gut-liver axis, and targeting key inflammatory components, have been proved to prevent HCC recurrence. This review article highlights the underlying mechanisms and promising therapeutic strategies to reduce tumor recurrence through alleviating inflammation induced by hepatic IRI.
Keywords
- hepatic
- ischemia/reperfusion injury
- inflammation
- hepatocellular carcinoma
- liver transplantation
- liver resection
